Rankings
▼
Calendar
PTCT Q4 2023 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
PTCT
PTC Therapeutics, Inc.
$6B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$307M
+83.4% YoY
Gross Profit
$201M
65.4% margin
Operating Income
$3M
1.0% margin
Net Income
-$156M
-50.7% margin
EPS (Diluted)
$-2.06
QoQ Revenue Growth
+56.2%
Cash Flow
Operating Cash Flow
-$100M
Free Cash Flow
-$129M
Stock-Based Comp.
$17M
Balance Sheet
Total Assets
$1.9B
Total Liabilities
$2.7B
Stockholders' Equity
-$819M
Cash & Equivalents
$594M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$307M
$167M
+83.4%
Gross Profit
$201M
$157M
+28.3%
Operating Income
$3M
-$200M
+101.6%
Net Income
-$156M
-$171M
+8.8%
Revenue Segments
Manufacturing
$3M
100%
Geographic Segments
United States
$344M
74%
Non-US
$118M
26%
← FY 2023
All Quarters
Q1 2024 →